Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/29942
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVermersch, P.-
dc.contributor.authorEralinna, J. -P.-
dc.contributor.authorNicholas, R.-
dc.contributor.authorOreja-Guevara, C.-
dc.contributor.authorSiva, A.-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorWiendl, H.-
dc.contributor.authorBuffels, R.-
dc.contributor.authorKuhelj, R.-
dc.contributor.authorWei, W.-
dc.contributor.authorComi, G.-
dc.date.accessioned2019-11-13T08:30:13Z-
dc.date.available2019-11-13T08:30:13Z-
dc.date.issued2019-
dc.identifier.citationMULTIPLE SCLEROSIS JOURNAL, 25(SI), p. 344-345 (Art N° P690)-
dc.identifier.issn1352-4585-
dc.identifier.urihttp://hdl.handle.net/1942/29942-
dc.description.sponsorshipSponsored by F. Hoffmann-La Roche Ltd; writing and editorial assistance was provided by Articulate Science, UK. P. Vermersch has received honoraria and consulting fees from Bayer, Biogen, Celgene, MedDay, Merck, Novartis, Roche, Sanofi Genzyme, Servier, Teva and Almirall, and research support from Bayer, Biogen, Merck, Novartis, Roche and Sanofi Genzyme.-
dc.language.isoen-
dc.publisherSAGE PUBLICATIONS LTD-
dc.subject.otherClinical Neurology; Neurosciences-
dc.titleEfficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results)-
dc.typeJournal Contribution-
local.bibliographicCitation.conferencedateSEP 11-13, 2019-
local.bibliographicCitation.conferencename35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS-
local.bibliographicCitation.conferenceplaceStockholm, SWEDEN-
dc.identifier.epage345-
dc.identifier.issueSI-
dc.identifier.spage344-
dc.identifier.volume25-
local.format.pages2-
local.bibliographicCitation.jcatM-
dc.description.notes[Vermersch, P.] Univ Lille, Lille, France. [Eralinna, J. -P.] NEO Res, Turku, Finland. [Nicholas, R.] Imperial Coll Healthcare NHS Trust, London, England. [Nicholas, R.] Imperial Coll, London, England. [Oreja-Guevara, C.] Hosp Clin San Carlos, Madrid, Spain. [Siva, A.] Istanbul Univ, Cerrahpasa Sch Med, Cerrahpasa, Turkey. [Van Wijmeersch, B.] Univ Hasselt, Overpelt, Belgium. [Van Wijmeersch, B.] Rehabil & MS Ctr Overpelt, Overpelt, Belgium. [Wiendl, H.] Univ Munster, Munster, Germany. [Buffels, R.; Kuhelj, R.; Wei, W.] F Hoffmann La Roche Ltd, Basel, Switzerland. [Comi, G.] Univ Vita Salute San Raffaele, Milan, Italy.-
local.publisher.placeLONDON-
local.type.refereedRefereed-
local.type.specifiedMeeting Abstract-
local.bibliographicCitation.artnrP690-
local.classdsPublValOverrule/author_version_not_expected-
dc.identifier.isi000485303101246-
item.fulltextNo Fulltext-
item.contributorVermersch, P.-
item.contributorEralinna, J. -P.-
item.contributorNicholas, R.-
item.contributorOreja-Guevara, C.-
item.contributorSiva, A.-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorWiendl, H.-
item.contributorBuffels, R.-
item.contributorKuhelj, R.-
item.contributorWei, W.-
item.contributorComi, G.-
item.fullcitationVermersch, P.; Eralinna, J. -P.; Nicholas, R.; Oreja-Guevara, C.; Siva, A.; VAN WIJMEERSCH, Bart; Wiendl, H.; Buffels, R.; Kuhelj, R.; Wei, W. & Comi, G. (2019) Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a suboptimal response to previous disease-modifying therapies (1-year interim results). In: MULTIPLE SCLEROSIS JOURNAL, 25(SI), p. 344-345 (Art N° P690).-
item.accessRightsClosed Access-
crisitem.journal.issn1352-4585-
crisitem.journal.eissn1477-0970-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.